

**OLYMPUS**

Your Vision, Our Future

# Financial Results for the Year Ended March 2007

---

**9<sup>th</sup> May 2007**

**Olympus Corporation**

**President: Tsuyoshi Kikukawa**

This presentation contains forward-looking statements that reflect management's current views, plans and expectations. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause Olympus's actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements.

# Consolidated Financial Results for the Year Ended March 31, 2007

**Historical highs for sales and income;  
1 trillion yen in net sales**

(Billions of yen)

	March 2006	March 2007	YoY change	
			Amount	Percentage change
<b>Net sales</b>	<b>978.1</b>	<b>1,061.8</b>	<b>+83.7</b>	<b>+8.6%</b>
<b>Operating income</b>	<b>62.5</b>	<b>98.7</b>	<b>+36.2</b>	<b>+57.9%</b>
<b>Ordinary income</b>	<b>41.2</b>	<b>76.2</b>	<b>+35.0</b>	<b>+85.0%</b>
<b>Net income</b>	<b>28.6</b>	<b>47.8</b>	<b>+19.2</b>	<b>+67.3%</b>

# Consolidated Forecast for the Year Ending March 31, 2008

**Renewed historical highs;  
Operating income above 100 billion yen.**


(Billions of yen)

	March 2007	March 2008	YoY change	
			Amount	Percentage change
<b>Net sales</b>	<b>1,061.8</b>	<b>1,150.0</b>	<b>+88.2</b>	<b>+8.3%</b>
<b>Operating income</b>	<b>98.7</b>	<b>107.0</b>	<b>+8.3</b>	<b>+8.4%</b>
<b>Ordinary income</b>	<b>76.2</b>	<b>85.0</b>	<b>+8.8</b>	<b>+11.5%</b>
<b>Net income</b>	<b>47.8</b>	<b>50.0</b>	<b>+2.2</b>	<b>+4.6%</b>

# Imaging Business

## ◆ Digital camera market

(Million units)



**Actual CIPA data (no. of compact and D-SLR units shipped on a fiscal year basis).  
The figure for fiscal year 2007 is Olympus' forecast.**

# Imaging Business

## ◆ Strengthen the digital SLR business

- 3 new models  
E410, E510, and successor to the E1

Target sales volume: Above 500,000 units  
(year-on-year double)



# Medical Business

## Single Balloon Enteroscope System

Already used in the esophagus, stomach, and large intestine, Narrow Band Imaging (NBI) is now also possible in the small bowel.

- ◆ **Easy-to-use and reduces in examination times.**
- ◆ **World-wide simultaneous launch in June 2007.**



By creating a lineup composed of Small Intestinal Videoscopes, Capsule Endoscopes, and EndoTherapy products, Olympus is now able to providing comprehensive value, from diagnosis to treatment, in the small bowel field.

# ITX

## ◆ Basic stance

- Equipment sales and service business
- Investment securities for business incubation



**OLYMPUS**

Your Vision, Our Future

Opto Digital Technology

**OLYMPUS**

Your Vision, Our Future

# Financial Results for the Year Ended March 2007

---

**9<sup>th</sup> May, 2007**  
**Olympus Corporation**

This presentation contains forward-looking statements that reflect management's current views, plans and expectations. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause Olympus's actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements.

# Consolidated Financial Results for the Year ended March 31, 2007

(Billions of Yen)

	March 2006	March 2007	YoY Change
Net Sales	978.1	1061.8	+8.6%
Operating Income	62.5	98.7	+57.9%
Ordinary Income	41.2	76.2	+85.0%
Net Income	28.6	47.8	+67.3%

# Results by Business Segments


# Consolidated Financial Results for the Year ended March 31, 2007 - by Business Segments

(Billions of Yen)


		March 2006	March 2007	YoY change
<b>Imaging</b>	Net Sales	254.5	294.3	+15.6%
	Operating Income	4.8	27.2	+467.8%
<b>Medical</b>	Net Sales	266.3	311.7	+17.0%
	Operating Income	76.6	87.9	+14.6%
<b>Life Science</b>	Net Sales	107.9	123.7	+14.6%
	Operating Income	7.6	8.1	+6.9%
<b>Information &amp; communication</b>	Net Sales	284.9	267.7	▲6.0%
	Operating Income	-2.6	2.7	---
<b>Others</b>	Net Sales	64.4	64.4	▲0.1%
	Operating Income	1.4	0.9	▲39.6%

# Imaging Business

## Sales




## Operating Income




# Medical Business

## Sales




## Operating Income

(¥ billion)




# Life Science Business

Sales




Operating Income



# Information and Communication


Sales

(¥ billion)



Operating Income

(¥ billion)




# Others

## Sales

Others

(¥ billion)


▲0.1%



## Operating Income

(¥ billion)

Operating Income OP Margin



# Consolidated Forecast for the Year Ending March 31, 2008

(Billions of Yen)

	March 2007	March 2008	YoY change
Net Sales	1,061.8	1,150.0	+8.3%
Operating Income	98.7	107.0	+8.4%
Ordinary Income	76.2	85.0	+11.5%
Net Income	47.8	50.0	+4.6%

# Forecast by business segments

(Billions of Yen)

		March 2007	March 2008	YoY change
<b>Imaging</b>	Net Sales	294.3	330.0	+12.1%
	Operating Income	27.2	25.0	▲8.1%
<b>Medical</b>	Net Sales	311.7	335.0	+7.5%
	Operating Income	87.9	100.0	+13.8%
<b>Life Science</b>	Net Sales	123.7	130.0	+5.1%
	Operating Income	8.1	8.5	+5.2%
<b>Information &amp; Communication</b>	Net Sales	267.7	283.0	+5.7%
	Operating Income	2.7	1.0	▲63.2%
<b>Others</b>	Net Sales	64.4	72.0	+11.8%
	Operating Income	0.9	1.5	+72.0%



**OLYMPUS**

Your Vision, Our Future


Opto Digital Technology

# Supplementary Information


# Depreciation /Capital Investments

(¥ billion)


■ Depreciation ■ Capital Investments




# R&D Expenditures



# Inventories



# Digital Camera Market



## Forecast for the Year ending March 31, 2008 - by Business Segments (1st half/2nd half)

(Billions of Yen)

		1 <sup>st</sup> Half	2 <sup>nd</sup> Half	Total
<b>Imaging</b>	Net Sales	150.0	180.0	330.0
	Operating Income	14.0	11.0	25.0
<b>Medical</b>	Net Sales	155.0	180.0	335.0
	Operating Income	43.0	57.0	100.0
<b>Life Science</b>	Net Sales	60.0	70.0	130.0
	Operating Income	1.6	6.9	8.5
<b>Information &amp; Communication</b>	Net Sales	132.5	150.5	283.0
	Operating Income	▲0.6	1.6	1.0
<b>Others</b>	Net Sales	32.5	39.5	72.0
	Operating Income	0	1.5	1.5
<b>Elimination Unallocation</b>	Net Sales	0	0	0
	Operating Income	▲ 15.0	▲ 14.0	▲ 29.0
<b>Total</b>	Net Sales	530.0	620.0	1,150.0
	Operating Income	43.0	64.0	107.0